Latest Articlesddd

Prohost Letter #385

October 21, 2015 0

Prohost Letter #385 An Evaluation of Prohost Picks and Some Other Interesting Biotechnology Companies The Top-Tier …

Sarepta vs. Biomarin: Trying to Make an Educated Guess

October 19, 2015 0

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to …

Incyte and Merck Agree to Expand Their Agreement Regarding Their Immunotherapy Combination Drugs

October 13, 2015 0

Incyte (INCY) and Merck (MRK) announced the expansion of their ongoing clinical collaboration to include a Phase …

Yesterday’s Market Performance Brings Back Hope to Normalcy. Compugen Announced Some Encouraging News

October 8, 2015 0

Stories from Yesterday’s Market We are not claiming that the market volatility has subsided and the …

Prohost Letter #384

October 6, 2015 0

Prohost Letter #384 The Assassination of the Biotech Sector The Market (Part 2) On Friday September 18, …

Xoma: A New Chance for Resurrection?

October 2, 2015 0

– Exclusively licenses global rights to its (TGFb) antibody program to Novartis  – Could the lucrative …

Exelixis: The Stream of Good News Continues to Flow

September 28, 2015 0

Exelixis (EXEL) announced positive results from the METEOR Phase 3 Pivotal Trial of Cabozantinib in advanced …

Prohost Letter #383

September 25, 2015 0

Prohost Letter #383 The Market - Recent tails about the market and the biotech sector are true …

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of a Promising Glaucoma Drug

September 17, 2015 0

Aerie Pharmaceuticals (AERI), which is specialized in glaucoma treatments reported successful results of its second Phase …

Huge Improvement in the Differential Diagnosis of Diseases and More

September 2, 2015 0

The biotechnology industry is proving to be the most innovative and the most growing among Wall …

Why Switzerland Approval of Exelixis and Roche Drug Combination for Melanoma Is a Big Deal

August 27, 2015 0

– The second approval of a cancer drug for Exelixis – The approval of Exelixis/Roche drugs …

A Letter To Prohost Subscribers

August 24, 2015 0

A Letter From Prohost The Stock Market Selloff What’s Going On and What Do We Do …

Seres Therapeutics: A Novel Approach for Treating Clostridium Difficile Infection

August 21, 2015 0

but first: Here is some good news from  SAREPTA Yesterday we wrote about BioMarin (BMRN) being …

Kite: News We Are Anxious to Hear

August 17, 2015 0

Kite Pharma (Kite) stock was sliding, raising concern about the firm and all the biotech firms …

Inovio Is in Much Better Shape Than Six Months Ago

August 13, 2015 0

INOVIO Inovio Pharmaceuticals (INO) is much worth looking at now than 6 months ago. The deal …

Astrazeneca Selects Mirati Therapeutics Drug for Its Cancer Immunotherapy Combination

August 6, 2015 0

In The NEWS IMMUNOTHERAPY MIRATI THERAPEUTICS Mirati Therapeutics (MRTX) is an oncology company focusing on genetic …

NantKwest Inc: A Novel Breathtaking Immunotherapy for Cancer?

August 3, 2015 0

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some …

Prohost Letter #381

July 31, 2015 0

Prohost Letter #381 QUARTERLY FINANCIAL RESULTS IN THE BIOTECH SECTOR Investors Concerns, Excitement and Expectations (Part …

Prohost Letter #380

July 27, 2015 0

Prohost Letter #380 Investors Concerns, Excitments and Expectations PART 2  REGENERON On Friday, July 24, Regeneron …

Exelixis: The Importance of the Public Offering. Xoma: What Should We Do Now?

July 23, 2015 0

Why the financing through a secondary public offering was a must for Exelixis. The outcome of …